Hyperthermia

In December 2025, the Danish Healthcare Quality Institute (DHQI) released a methodological document clarifying the processes of health economic analyses associated with the clinical guidelines and the DHQI Council’s decision-making. Furthermore, the first two health economic analyses associated with the clinical guidelines were published concerning prostate-specific membrane antigen (PSMA)-PET/CT in prostate cancer and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

On June 10, 2025, the Swiss Federal Office of Public Health published updates to the Healthcare Benefit Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The changes will take effect on July 1, 2025, and relate to colorectal cancer screening with the increase in the number of reimbursed colonoscopies, cancer treatment, men’s health, medical aids, and other medical services.

In March 2025, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned the results of the studies provided within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs NICE guidance.

On July 3, 2023, the document "Changes and innovations in the 2024 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2024) was published. The document summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes mainly concern endoscopic procedures, orthopedics, peripheral vascular, and pulmonary and airways fields.

In early November 2019, the report of the project OTCA18, titled “Regional hyperthermia for high-risk soft tissue sarcoma treatment” was published on the website of the European Network for HTA (EUnetHTA).

In mid-May 2019, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA18 “Regional hyperthermia for high-risk soft tissue sarcoma treatment.”